Journal Article

Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium

J. Bellmunt, S. Albiol, A. Ramírez de Olano, J. Pujadas and P. Maroto

in Annals of Oncology

Published on behalf of European Society for Medical Oncology

Volume 17, issue suppl_5, pages v113-v117
Published in print May 2006 | ISSN: 0923-7534
Published online May 2006 | e-ISSN: 1569-8041 | DOI: http://dx.doi.org/10.1093/annonc/mdj964
Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium

Show Summary Details

Preview

M-VAC (cisplatin, methotrexate, adriamycin, vinblastine) combination chemotherapy has been for long time the standard of care in fit patient with advanced urothelial tumors. Gemcitabine/cisplatin with similar results and an improved toxicity profile has proved to be a new standard alternative. Whether or not we can improve survival with newer triplet regimens will depend upon the results of ongoing phase III trials. In addition to the new active drug combinations and targeted therapies, new approaches are emerging for treatment. Chemotherapy optimization using molecular markers predicting chemosensitivity are being applied. There is an obvious need to incorporate in clinical trials a systematic translational approach to explain both our successes and our failures.

Keywords: bladder cancer; chemotherapy; gemcitabine; urothelial cell cancer

Journal Article.  0 words. 

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.